Yagame M, Tomino Y, Miura M, Suga T, Endoh M, Nomoto Y, Sakai H
Department of Internal Medicine, School of Medicine, Tokai University, Japan.
Tokai J Exp Clin Med. 1986 Nov;11(5):329-33.
Clinical effects of dipyridamole and carbazochrome sodium sulfonate in patients with IgA nephropathy are described. Oral administration of 300 mg of dipyridamole and 180 mg of carbazochrome sodium sulfonate per day was employed in the present study. Urinalysis and renal function tests, i.e. serum creatinine (s-Cr), blood urea nitrogen (BUN), glomerular filtration rate (GFR) and phenolsulfonphtalein (PSP) tests, were performed before and after the administration of dipyridamole. It was demonstrated that the administration of dipyridamole was effective in reducing the level of proteinuria in the patients. The administration of carbazochrome sodium sulfonate was not effective in reducing the proteinuria level. It was concluded that the administration of dipyridamole may be useful for treatment of patients with IgA nephropathy.
描述了双嘧达莫和卡巴克络磺酸钠对IgA肾病患者的临床疗效。本研究采用每日口服300mg双嘧达莫和180mg卡巴克络磺酸钠的方法。在服用双嘧达莫前后进行了尿液分析和肾功能测试，即血清肌酐（s-Cr）、血尿素氮（BUN）、肾小球滤过率（GFR）和酚磺酞（PSP）测试。结果表明，服用双嘧达莫可有效降低患者的蛋白尿水平。卡巴克络磺酸钠对降低蛋白尿水平无效。得出结论，双嘧达莫给药可能对IgA肾病患者的治疗有用。
